10/08/2025
Cidara Therapeutics has announced it will receive federal backing to advance its influenza preventive CD388, following the re acquisition of rights to the asset last year. The U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) has awarded Cidara Therapeutics up to $339 million to support development and domestic production of this innovative therapy.